Home Compare GSK.L vs NOVO-B.CO
Stock Comparison · Industry comparison · Drug Manufacturers - General

GSK vs Novo Nordisk A/S: Which Stock Looks Stronger in 2026?

Novo Nordisk A/S holds the cleaner structural position, with growth as the main driver and stability adding further support. GSK still has the edge on stability, which keeps the comparison from looking entirely one-sided. In the market, GSK carries the stronger setup — intact trend against Novo Nordisk A/S's broken trend. That leaves a split case: the structural lead stays with Novo Nordisk A/S, but the market is not currently confirming it.

The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the STOXX 600 universe, making them directly comparable.

Updated 2026-05-17

Most of the lead runs through growth, while profitability helps make the separation broader. The overall score gap is 10 points in favour of Novo Nordisk A/S.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. GSK.L and NOVO-B.CO share the same industry classification.

For a similarity-based comparison, see how GSK and Novo Nordisk A/S each position within their functional peer groups in AssetNext.

Peer-Relative Score
GSK.L
GSK plc
67
Peer-Score
Signal qualityMedium
Peer basis: STOXX 600
vs
NOVO-B.CO
Novo Nordisk A/S
77
Peer-Score
Signal qualitylow
Peer basis: STOXX 600

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Score differences across key dimensions.

Dimension spread: GSK.L vs NOVO-B.CO Profitability 68 91 Stability 76 34 Valuation 84 88 Growth 30 80 GSK.L NOVO-B.CO
Gap Ranking
#1 Growth +50
#2 Stability +42
#3 Profitability +23
#4 Valuation +4
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for GSK.L and NOVO-B.CO Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer GSK.LNOVO-B.CO Relative valuation Structural strength

Novo Nordisk A/S looks stronger on relative valuation, while the broader price setup remains mixed.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
On growth, Novo Nordisk A/S ranks near the top of the group; GSK plc sits in the weaker half.
Stability
On stability, the gap still runs the same way: GSK plc sits near the top of the group, while Novo Nordisk A/S remains in the weaker half.
Growth — Dominant Gap
GSK.L
30
NOVO-B.CO
80
Gap+50in favour of NOVO-B.CO

Revenue growth reinforces the category-level growth lead.

What keeps the gap from being one-sided

There is still a strong counterforce in stability, so the lead stays clear without becoming a sweep.

What this means for the comparison

The growth edge is decisive, but stability still pushes back — the result holds, but not without a real counterweight.

Explore full peer positioning in AssetNext

Break down the GSK.L vs NOVO-B.CO comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how GSK.L and NOVO-B.CO each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.